Acth-Independent Cushing Syndrome

Watchlist

(log in to enable)

Retrieved

2021-01-23

Source

Orphanet

Trials

—

Genes

GNAS, ARMC5, GCGR, POMC, PRKAR1A, PDE11A, AVP, MC2R, EDNRA, GPRC6A, LPAR2, CXCR6, CLASP2, VN1R17P, LPAR3, SPINK4, LGR6, ACKR3, MRGPRX1, FZD4, DOT1L, MRGPRX3, MRGPRX4, GPR151, OXER1, CCN5, ADRA1A, SSTR4, GIPR, ADRA2B, SERPINC1, BRS3, EPHA3, GABBR1, GAPDH, GIP, GPR42, SCG5, NR3C1, HTR4, LHCGR, MEN1, MLN, PRKACA, ADRA2A, GPR166P

Drugs

2S,4R ketoconazole, Ketoconazole ( KETOCONAZOLE HRA, NIZORAL ), Linsitinib

2S,4R ketoconazole, Ketoconazole ( KETOCONAZOLE HRA, NIZORAL ), Linsitinib, Mifepristone ( KORLYM ), Mitotane ( LYSODREN ), Nevanimibe, Osilodrostat ( ISTURISA )

Interested in hearing about new therapies?

A form of endogenous Cushing syndrome (CS) that may result from excess secretion of cortisol by either a unilateral and benign (adrenocortical adenoma: 55-60%) or malignant (adrenocortical carcinoma: 35-40 %) adrenocortical tumor or by bilateral adrenal secretion by macronodular adrenal hyperplasia (AIMAH), as an isolated disease or as part of McCune-Albright syndrome (MAS), or by primary pigmented nodular adrenocortical disease (PPNAD), as an isolated disease or as part of Carney complex (CNC).